Macrophage Pharma is developing a highly novel class of small molecule therapeutics which modulate immune responses to combat cancer based on its proprietary Esterase Motif Technology (ESM™) platform. ESM™ molecules deliver small molecule inhibitors of key intracellular targets in a highly selective manner to macrophages, monocytes and monocyte-derived dendritic cells. Macrophage Pharma is rapidly progressing its lead molecules to the clinic utilising ESM™ to deliver inhibitors to tumour associated macrophages and tolerogenic dendritic cells in the tumour microenvironment.
The Company was founded by the CRT Pioneer Fund and recently announced a £9 million financing round. The round was led by CPF who were joined by two specialist investors, Novo A/S and Aglaia Biomedical Ventures BV. The proceeds of the financing round will enable the Company to complete the pre-clinical development of its lead development candidate, a p38 MAP kinase inhibitor, and advance two additional discovery candidates into pre-clinical development.
The company’s management team has track record of success in the pharma industry ranging from early discovery to commercialisation. The Scientific Advisory Board is comprised of world-leading immunologists and cancer researchers who will help shape the future development of our unique approach in immuno-oncology.